 |
Nebacumab |
|---|---|
| Trade Name | Centoxin |
| Orphan Indication | Patients with gram-negative bacteremia which has progressed to endotoxin shock |
| USA Market Approval | USA |
| USA Designation Date | 1986-10-01 00:00:00 |
| Sponsor | Centocor, Inc.;244 Great Valley Parkway;Malvern, Pennsylvania, 19355 |
